Last reviewed · How we verify
MT-201
At a glance
| Generic name | MT-201 |
|---|---|
| Sponsor | Mirador Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease (PHASE2)
- A First-in-Human Single and Multiple Ascending Dose Study of MT-201 (PHASE1)
- Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (PHASE1)
- Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-201 CI brief — competitive landscape report
- MT-201 updates RSS · CI watch RSS
- Mirador Therapeutics, Inc. portfolio CI